Loading stock data…
$153.11+1.78 (+1.18%)
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.
Twist Bioscience Corporation in the Healthcare sector is trading at $153.11 with a market capitalization of $9.2B. Wall Street consensus targets $163.67 (12 analysts), implying a +6.9% move over the next 12 months. The stock is currently 30% below its 52-week high of $219.71, remaining 86.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $118.38M↑ | $110.72M↑ | $103.70M↑ | $99.01M↑ | $96.06M |
| Gross Profit | $62.45M↑ | $57.12M↑ | $53.97M↑ | $50.84M↓ | $51.30M |
| Operating Income | -$36.28M↑ | -$38.66M↓ | -$33.10M↓ | -$29.93M↑ | -$30.12M |
| Net Income | -$35.05M↑ | -$44.02M↓ | -$30.51M↓ | -$27.14M↓ | $20.39M |
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, an...